Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
1. Viking's VK2735 shows significant weight loss in Phase 2 trial. 2. LLY's orforglipron previously underperformed compared to VK2735 results. 3. VK2735 achieved up to 12.2% weight loss, safe and well-tolerated. 4. Analysts suggest VK2735 could capitalize on LLY's recent setback. 5. Viking's trial data reflects potential market competition for LLY.